NASDAQ:MGX • US59102M1045
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for METAGENOMI THERAPEUTICS INC (MGX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-14 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-14 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-18 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-12-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-15 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-07-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-07 | HC Wainwright & Co. | Initiate | Buy |
| 2024-05-02 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2024-03-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-03-05 | TD Cowen | Initiate | Outperform |
| 2024-03-05 | Chardan Capital | Initiate | Buy |
| 2024-03-05 | BMO Capital | Initiate | Outperform |
| 2024-03-05 | Wells Fargo | Initiate | Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 44.756M 160.21% | 52.295M 16.84% | 25.21M -51.79% | 22.214M -11.88% | 24.165M 8.78% | 14.336M -40.67% | 10.1M -29.55% | 22.725M 125.00% | 59.567M 162.12% | 318.27M 434.31% | 607.74M 90.95% | |
| EBITDA YoY % growth | -74.285M -73.13% | -83.494M -12.40% | -90.696M -8.63% | -109.282M -20.49% | -144.43M -32.16% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -78.492M -75.83% | -88.901M -13.26% | -96.013M -8.00% | -95.553M 0.48% | -113.158M -18.42% | -114.248M -0.96% | -131.333M -14.95% | -140.342M -6.86% | -117.539M 16.25% | 98.21M 183.56% | 384.68M 291.69% | |
| Operating Margin | -175.38% | -170.00% | -380.85% | -430.15% | -468.27% | -796.93% | -1,300.33% | -617.56% | -197.32% | 30.86% | 63.30% | |
| EPS YoY % growth | N/A | -2.62 52.12% | -2.37 9.54% | -1.84 22.46% | -1.62 11.89% | -1.20 25.78% | -1.41 -17.65% | -1.38 2.14% | -0.92 33.58% | 0.84 191.21% | 3.09 268.67% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.53 21.77% | -0.53 1.15% | -0.56 -1.18% | -0.58 3.63% |
| Revenue Q2Q % growth | 6.632M 60.70% | 5.05M -40.68% | 5.05M -41.68% | 5.05M 29.12% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -21.463M 22.85% | -20.301M 3.27% | -20.907M 8.46% | -21.513M 11.71% |
All data in USD
9 analysts have analysed MGX and the average price target is 9.52 USD. This implies a price increase of 535.22% is expected in the next year compared to the current price of 1.4987.
METAGENOMI THERAPEUTICS INC (MGX) will report earnings on 2026-05-08.
The consensus EPS estimate for the next earnings of METAGENOMI THERAPEUTICS INC (MGX) is -0.53 USD and the consensus revenue estimate is 6.63M USD.
The consensus rating for METAGENOMI THERAPEUTICS INC (MGX) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.